Jubilant Therapeutics Reports Preliminary P-I Data of JBI-802 for Essential Thrombocythemia and Related MPNs

Shots: Jubilant Therapeutics has reported preliminary data from the P-I portion of the P-I/II (JBI-802-02) study of JBI-802 (oral dual LSD1/HDAC6 inhibitor) in pts with r/r or intolerant ET, PV & MDS/MPN with thrombocytosis, selected for an oral presentation at ASH 2026 As of Jun 30, 2026, all 8 pts on 15mg achieved >50% platelet reduction or normalization by Wk. 3 (median time to response: 15 days), with normalization maintained through 33, 44 & 46wks.; 7/11 pts with leukocytosis at 15mg achieved CHR No DLTs were observed at 5, 7 or 15mg; further efficacy, safety & molecular data will be presented at ASH on Dec 14, 2026 Ref: PR Newswire  |   Image: Jubilant Therapeutics  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Jubilant Therapeutics Reports Preliminary P-I Data of JBI-802 for Essential Thrombocythemia and Related MPNs appeared first on PharmaShots.